




# Innovative Patented Probiotic Strain for Cardiometabolic Health

What distinguishes LP<sub>LDL</sub><sup>®</sup> from other probiotic strains is its remarkable efficacy in improving cardiometabolic biomarkers.

Elevated levels of cardiometabolic biomarkers are commonly tackled by approaches that come with multiple undesirable side effects, however LP<sub>LDL</sub><sup>®</sup> offers a scientifically backed and natural alternative to support cardiometabolic health and has seen no observed side effects in multiple human intervention studies.







## The 1 in 4000 probiotic

Selected out of 4000 strains to support cardiometabolic health.



### SCIENTIFICALLY VALIDATED

Supports multiple **cardiometabolic health** biomarkers


-  Total Cholesterol
-  LDL Cholesterol
-  HDL Cholesterol
-  Apolipoprotein B (contributor to plaque formation)
-  Triglycerides
-  Blood Pressure

## The link between the gut microbiome & cardiometabolic health

### GUT-LIVER AXIS

The liver and the gut microbiome have an intense functional and bidirectional communication known as the Gut-Liver Axis. Within this metabolic cooperation, the liver produces and releases bile salts influencing cholesterol metabolism.

LP<sub>LDL</sub><sup>®</sup> deconjugates bile salts in the gut, preventing their uptake by the liver. This triggers the liver to utilise cholesterol to restore the bile acid pool.





Scientifically validated in independent human intervention studies to support **cardiometabolic health**

STRUCTURE FUNCTION CLAIMS\*

- > Helps maintain cholesterol levels already in the normal range
- > Supports normal LDL and HDL cholesterol levels
- > Positive effect on cholesterol levels within the normal range


\*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

STUDY 1

Safety and efficacy of LP<sub>LDL</sub>® in normal to mildly hypercholesterolemic adults

A 12-week, independent, double blind, randomised, placebo controlled human intervention in subjects taking 4x10<sup>9</sup> CFU encapsulated LP<sub>LDL</sub>® or placebo.

Volunteers consumed 4x10<sup>9</sup> CFU/day LP<sub>LDL</sub>® or placebo in DR capsules. The study showed LP<sub>LDL</sub>® to be completely safe and well tolerated with statistically significant changes observed in multiple cardiometabolic biomarkers.



University of Reading: Costabile et al., 2017

STUDY 2

Efficacy of LP<sub>LDL</sub>® in hypercholesterolemic adults

A 9-week, independent, double blind, randomised, placebo controlled human intervention study taking 4x10<sup>9</sup> CFU encapsulated LP<sub>LDL</sub>® or placebo.

LP<sub>LDL</sub>® was shown to be completely safe, well-tolerated and showcased statistically significant improvements in multiple cardiometabolic biomarkers within 6 weeks.



University of Roehampton: Keleszade E. et al., 2021

LP<sub>LDL</sub>® is available in our range of finished formulations for **cardiometabolic health**

The YourBiotix product range is a full turn-key solution ready for your branding.



probiotixhealth.com

© 2024 ProBiotix Health. All rights reserved.

